Overview

Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This study will establish a clinical data and serum repository of anaphylaxis cases associated with Xolair administration and control patients who have received Xolair without associated anaphylaxis. This is an observational repository and not an investigational clinical trial. Associated with the repository is an optional skin testing substudy.
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Omalizumab